SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Opko Health, Inc. – ‘10-K’ for 12/31/19 – ‘EX-10.36’

On:  Monday, 3/2/20, at 5:29pm ET   ·   For:  12/31/19   ·   Accession #:  944809-20-7   ·   File #:  1-33528

Previous ‘10-K’:  ‘10-K’ on 3/1/19 for 12/31/18   ·   Next:  ‘10-K’ on 2/18/21 for 12/31/20   ·   Latest:  ‘10-K’ on 3/1/24 for 12/31/23   ·   1 Reference:  By:  Opko Health, Inc. – Next ‘10-K’ on 2/18/21 for 12/31/20

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/02/20  Opko Health, Inc.                 10-K       12/31/19  111:16M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.49M 
 2: EX-4.6      Instrument Defining the Rights of Security Holders  HTML     39K 
 3: EX-10.36    Material Contract                                   HTML     60K 
 4: EX-10.37    Material Contract                                   HTML     50K 
 5: EX-10.38    Material Contract                                   HTML     65K 
 6: EX-21       Subsidiaries List                                   HTML     32K 
 7: EX-23.1     Consent of Experts or Counsel                       HTML     32K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     36K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     36K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     30K 
11: EX-32.2     Certification -- §906 - SOA'02                      HTML     30K 
88: R1          Cover Page                                          HTML     92K 
24: R2          Consolidated Balance Sheets                         HTML    125K 
60: R3          Consolidated Balance Sheets (Parenthetical)         HTML     38K 
98: R4          Consolidated Statements of Operations               HTML     99K 
85: R5          Consolidated Statements of Comprehensive Loss       HTML     53K 
21: R6          Consolidated Statements of Equity                   HTML     89K 
59: R7          Consolidated Statements of Cash Flows               HTML    151K 
96: R8          Consolidated Statements of Cash Flows               HTML     31K 
                (Parenthetical)                                                  
89: R9          Business and Organization                           HTML     35K 
40: R10         Summary of Significant Accounting Policies          HTML     86K 
52: R11         Loss Per Share                                      HTML     36K 
108: R12         Investments                                         HTML     61K  
73: R13         Composition of Certain Financial Statement          HTML    216K 
                Captions                                                         
39: R14         Debt                                                HTML    135K 
51: R15         Shareholders' Equity                                HTML     40K 
107: R16         Accumulated Other Comprehensive Income (Loss)       HTML     50K  
72: R17         Equity-Based Compensation                           HTML     79K 
38: R18         Income Taxes                                        HTML    162K 
53: R19         Related Party Transactions                          HTML     49K 
91: R20         Employee Benefit Plans                              HTML     32K 
81: R21         Commitments and Contingencies                       HTML     47K 
18: R22         Revenue Recognition                                 HTML    118K 
55: R23         Strategic Alliances                                 HTML     55K 
90: R24         Leases                                              HTML    128K 
80: R25         Segments                                            HTML    140K 
17: R26         Fair Value Measurements                             HTML    111K 
54: R27         Derivative Contracts                                HTML     55K 
92: R28         Selected Quarterly Financial Data (Unaudited)       HTML     62K 
79: R29         Subsequent Events                                   HTML     34K 
74: R30         Summary of Significant Accounting Policies          HTML    148K 
                (Policies)                                                       
110: R31         Investments (Tables)                                HTML     51K  
49: R32         Composition of Certain Financial Statement          HTML    216K 
                Captions (Tables)                                                
36: R33         Debt (Tables)                                       HTML    101K 
76: R34         Accumulated Other Comprehensive Income (Loss)       HTML     50K 
                (Tables)                                                         
111: R35         Equity-Based Compensation (Tables)                  HTML     68K  
50: R36         Income Taxes (Tables)                               HTML    159K 
37: R37         Revenue Recognition (Tables)                        HTML     94K 
78: R38         Leases (Tables)                                     HTML    121K 
109: R39         Segments (Tables)                                   HTML    143K  
82: R40         Fair Value Measurements (Tables)                    HTML    110K 
94: R41         Derivative Contracts (Tables)                       HTML     57K 
63: R42         Selected Quarterly Financial Data (Unaudited)       HTML     62K 
                (Tables)                                                         
25: R43         Business and Organization (Details)                 HTML     30K 
83: R44         Summary of Significant Accounting Policies          HTML    141K 
                (Details)                                                        
95: R45         Loss Per Share - Narrative (Details)                HTML     42K 
64: R46         Investments - Accounting Method, Carrying Value     HTML     44K 
                and Underlying Equity in Net Assets of                           
                Unconsolidated Investments (Details)                             
26: R47         Investments - Narrative (Details)                   HTML    108K 
84: R48         Investments - Schedule of Net Gains and Losses on   HTML     35K 
                Equity Securities (Details)                                      
93: R49         Composition of Certain Financial Statement          HTML    190K 
                Captions (Details)                                               
101: R50         Composition of Certain Financial Statement          HTML     64K  
                Captions - Narrative (Details)                                   
67: R51         Composition of Certain Financial Statement          HTML     44K 
                Captions - Changes in Allowance for Doubtful                     
                Accounts, Provision for Inventory Reserve and Tax                
                Valuation (Details)                                              
35: R52         Composition of Certain Financial Statement          HTML     71K 
                Captions - Changes in Goodwill (Detail)                          
48: R53         Debt - Narrative (Details)                          HTML    244K 
100: R54         Debt - Schedule of Notes (Details)                  HTML     68K  
66: R55         Debt - Lines of Credit (Details)                    HTML     70K 
34: R56         Debt - Mortgage Notes and Other Debt (Details)      HTML     39K 
47: R57         Shareholders' Equity - Narrative (Details)          HTML     82K 
102: R58         Accumulated Other Comprehensive Income (Loss)       HTML     55K  
                (Details)                                                        
65: R59         Equity-Based Compensation - Narrative (Details)     HTML     82K 
23: R60         Equity-Based Compensation - Option-Pricing Formula  HTML     48K 
                (Details)                                                        
61: R61         Equity-Based Compensation - Summary of Option       HTML     85K 
                Activity (Details)                                               
99: R62         Income Taxes - Benefits (Provision) for Income      HTML     60K 
                Taxes (Details)                                                  
87: R63         Income Taxes - Deferred Income Taxes (Details)      HTML    103K 
22: R64         Income Taxes - Narrative (Details)                  HTML     66K 
58: R65         Income Taxes - Change in Gross Unrecognized Income  HTML     42K 
                (Details)                                                        
97: R66         Income Taxes - Difference in Federal and Effective  HTML     70K 
                Tax Rate (Details)                                               
86: R67         Income Taxes - Reconciliation Losses Before Tax,    HTML     36K 
                US and Foreign Jurisdictions (Details)                           
19: R68         Related Party Transactions - Narrative (Details)    HTML    261K 
62: R69         Employee Benefit Plans (Details)                    HTML     38K 
43: R70         Commitments and Contingencies (Details)             HTML     50K 
27: R71         Revenue Recognition - Narrative (Details)           HTML     62K 
68: R72         Revenue Recognition - Schedule of Disaggregation    HTML     49K 
                of Revenue (Details)                                             
103: R73         Revenue Recognition - Schedule of Product Sales     HTML     65K  
                Allowances and Accruals (Details)                                
46: R74         Strategic Alliances (Details)                       HTML    120K 
31: R75         Leases - Lease Assets and Liabilities (Details)     HTML     57K 
71: R76         Leases - Lease Liability Maturity (Details)         HTML     69K 
106: R77         Leases (Details)                                    HTML     36K  
41: R78         Leases - Supplemental Cash Flow Information         HTML     37K 
                (Details)                                                        
32: R79         Segments - Narrative (Details)                      HTML     39K 
44: R80         Segments - Operating Segments (Details)             HTML    116K 
29: R81         Segments - Reconciliation Property Plant and        HTML     40K 
                Equipment, US and Foreign Jurisdictions (Details)                
69: R82         Fair Value Measurements - Assets and Liabilities    HTML     64K 
                Measured at Fair Value (Details)                                 
104: R83         Fair Value Measurements - Carrying Amount and       HTML     40K  
                Estimated Fair Value of Long-Term Debt (Details)                 
45: R84         Fair Value Measurements - Level 3 Reconciliation    HTML     35K 
                (Details)                                                        
30: R85         Fair Value Measurements - Narrative (Details)       HTML     41K 
70: R86         Derivative Contracts - Fair Value and Presentation  HTML     44K 
                (Details)                                                        
105: R87         Derivative Contracts - Losses and Gains on          HTML     39K  
                Derivative Instruments (Details)                                 
42: R88         Selected Quarterly Financial Data (Unaudited)       HTML     45K 
                (Details)                                                        
33: R89         Subsequent Events (Details)                         HTML     58K 
77: R9999       Uncategorized Items - opk-12312019x10k.htm          HTML     35K 
57: XML         IDEA XML File -- Filing Summary                      XML    194K 
56: XML         XBRL Instance -- opk-12312019x10k_htm                XML   4.13M 
28: EXCEL       IDEA Workbook of Financial Reports                  XLSX    150K 
13: EX-101.CAL  XBRL Calculations -- opk-20191231_cal                XML    349K 
14: EX-101.DEF  XBRL Definitions -- opk-20191231_def                 XML   1.31M 
15: EX-101.LAB  XBRL Labels -- opk-20191231_lab                      XML   2.92M 
16: EX-101.PRE  XBRL Presentations -- opk-20191231_pre               XML   1.78M 
12: EX-101.SCH  XBRL Schema -- opk-20191231                          XSD    261K 
20: JSON        XBRL Instance as JSON Data -- MetaLinks              574±   835K 
75: ZIP         XBRL Zipped Folder -- 0000944809-20-000007-xbrl      Zip    652K 


‘EX-10.36’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  


EXECUTION VERSION


 
AMENDMENT NO. 10 TO CREDIT AGREEMENT
AMENDMENT NO. 10 TO CREDIT AGREEMENT (this “Amendment”), dated as of November 4, 2019, is entered into among BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation (“Company”), the Subsidiary Borrowers party hereto (“Subsidiary Borrowers,” and together with Company, each a “Borrower” and, collectively, the “Borrowers”), the other Loan Parties party hereto, the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as the administrative agent for the Lenders (the “Administrative Agent”).

W I T N E S S E T H :
WHEREAS, the Borrowers, the other Loan Parties party thereto, the Lenders party thereto, and the Administrative Agent have executed and delivered that certain Credit Agreement dated as of November 5, 2015, as amended by Amendment No. 1 to Credit Agreement dated as of February 29, 2016, as amended by Amendment No. 2 to Credit Agreement dated as of September 26, 2016, as amended by Amendment No. 3 to Credit Agreement dated as of March 17, 2017, as amended by Amendment No. 4 to Credit Agreement dated as of August 7, 2017, as amended by Amendment No. 5 to Credit Agreement dated as of November 8, 2017, as amended by Amendment No. 6 to Credit Agreement dated as of December 22, 2017, as amended by Waiver Under and Amendment No. 7 to Credit Agreement dated as of February 28, 2018, as amended by Amendment No. 8 to Credit Agreement dated as of February 26, 2019, and as amended by Amendment No. 9 to Credit Agreement dated as of August 6, 2019 (as further amended, restated, supplemented, or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”); and

WHEREAS, the Borrowers have requested that the Lenders and the Administrative Agent make certain amendments to the Credit Agreement, and the Lenders party hereto, constituting all Lenders under the Credit Agreement, have agreed to such amendments, subject to the terms and conditions hereof.
NOW, THEREFORE, for and in consideration of the above premises and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, each of the Borrowers, the other Loan Parties, the Lenders and the Administrative Agent hereby covenant and agree as follows:
SECTION 1. Definitions. Unless otherwise specifically defined herein, each term used herein (and in the recitals above) which is defined in the Credit Agreement shall have the meaning assigned to such term in the Credit Agreement. As of the date hereof, each reference in the Credit Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference in the other Loan Documents to the Credit Agreement (including, without limitation, by means of words like “thereunder,” “thereof” and words of like import), shall mean and be a reference to the Credit Agreement, as amended hereby.
SECTION 2. Amendments to Credit Agreement. Effective upon the satisfaction of the conditions precedent set forth in Section 3, the Credit Agreement is hereby amended as follows:



NAI-1509566825v8


(a)    Section 1.01 of the Credit Agreement is hereby amended by adding the following definition of “Amendment No. 10 Effective Date” in appropriate alphabetical order:
Amendment No. 10 Effective Date” means November 4, 2019.
(b)    Each of the following definitions in Section 1.01 of the Credit Agreement is hereby amended so that it reads in its entirety as follows:
Aggregate Revolving Commitment” means, at any time, the aggregate of the Revolving Commitments of all of the Lenders, as increased or reduced from time to time pursuant to the terms and conditions hereof. As of the Amendment No. 10 Effective Date, the Aggregate Revolving Commitment is $75,000,000.
Borrowing Base” means, at any time, the sum of (a) the lesser of (i) 70% of the Borrowers’ Eligible Accounts at such time and (ii) the Borrowers’ Eligible Collected A/R Amount at such time minus (b) Reserves.
The aggregate amount of Eligible Accounts attributable to any Borrower at any time shall not exceed the aggregate amount of net Accounts calculated in accordance with GAAP attributable to such Borrower as set forth on the most recent Borrowing Base Certificate delivered to the Administrative Agent pursuant to Section 5.01(g) of this Agreement.
The Administrative Agent may, in its Permitted Discretion, reduce the advance rates set forth above, adjust Reserves or reduce one or more of the other elements used in computing the Borrowing Base, with any such changes to be effective three (3) Business Days after receipt of written notice thereof by the Borrower Representative and the Lenders. The Borrowing Base at any time shall be determined by reference to the most recent Borrowing Base Certificate delivered to the Administrative Agent pursuant to Section 5.01(g) of this Agreement. It is acknowledged and agreed that on and after the Amendment No. 10 Effective Date, the $5,000,000 Reserve imposed by the Administrative Agent prior to the Amendment No. 10 Effective Date applicable to all Borrowing Base Certificates delivered on and after January 2019 shall no longer be imposed; provided, however, that the Administrative Agent shall retain its right in its Permitted Discretion to impose Reserves in the future in accordance with the terms of this Agreement.
Maturity Date” means November 5, 2021, or any earlier date on which the Commitments are reduced to zero or otherwise terminated pursuant to the terms hereof.
(c)    The Administrative Agent and the Lenders agree that the Revolving Commitment of each of the Lenders immediately after the effectiveness of this Amendment in accordance with its terms on the date hereof and as of the Amendment No. 10 Effective Date, shall be as set forth on the Commitment Schedule attached as Exhibit A hereto.



NAI-1509566825v8    2


SECTION 3. Conditions Precedent. This Amendment shall become effective on the date the following conditions precedent shall have been satisfied:
(a)    the Administrative Agent shall have received signatures to this Amendment from the parties listed on the signature pages hereto;
(b)    the Administrative Agent shall have received a certificate of each Loan Party dated the Amendment No. 10 Effective Date and executed by its Secretary or Assistant Secretary, which shall (i) certify the resolutions of its Board of Directors, members or other body authorizing the execution, delivery and performance of this Amendment, and (ii) contain appropriate attachments, including (A) a true and correct copy of the certificate or articles of incorporation or organization of each Loan Party, (B) a true and correct copy of its bylaws or operating, management or partnership agreement, or other organizational or governing documents, and (C) a good standing certificate for each Loan Party from its jurisdiction of organization or the substantive equivalent available in the jurisdiction of organization for each Loan Party from the appropriate governmental officer in such jurisdiction;
(c)    the Administrative Agent shall have received a written opinion of the Loan Parties’ counsel, addressed to the Administrative Agent, the Issuing Bank and the Lenders, in form and substance reasonably satisfactory to the Administrative Agent and its counsel;
(d)    the Administrative Agent shall have received, for the benefit of the Lender, an amendment fee equal to $45,000 (the “Amendment Fee”), and such Amendment Fee shall be (i) deemed fully earned and due and payable upon satisfaction of all of the other conditions to the effectiveness of this Amendment set forth in this Section 3, and (ii) nonrefundable;
(e)    the Administrative Agent shall have received an amount, if any, such that, after giving effect to this Amendment, the principal amount of all Loans outstanding on the date hereof shall not exceed the lesser of (A) the Aggregate Revolving Commitment (after giving effect to this Amendment) minus Reserves and (B) the Borrowing Base (after giving effect to this Amendment); and
(f)    the Administrative Agent shall have received from the Borrowers (or the Administrative Agent shall be satisfied with arrangements made for the payment thereof) all other costs, fees, and expenses owed by the Borrowers to the Administrative Agent in connection with this Amendment, including, without limitation, reasonable attorneys’ fees and expenses, in accordance with Section 9.03 of the Credit Agreement.
SECTION 4. Miscellaneous.
(a)    Representations and Warranties. To induce the Administrative Agent and Lenders to enter into this Amendment, the Borrowers hereby represent and warrant to the Administrative Agent and the Lenders that all representations and warranties of the Borrowers contained in Article III of the Credit Agreement or any other Loan Document are true and correct in all material respects with the same effect as though made on and as of the date hereof (except with respect to representations and warranties made as of an expressed date, which representations and warranties



NAI-1509566825v8    3


are true and correct in all material respects as of such date). For the avoidance of doubt, the parties hereto acknowledge that the Borrowing Base for the Borrowing Base Reporting Date of September 30, 2019 shall be calculated prior to giving effect to this Amendment.
(b)    No Offset. To induce the Administrative Agent and Lenders to enter into this Amendment, the Borrowers hereby acknowledge and agree that, as of the date hereof, and after giving effect to the terms hereof, there exists no right of offset, defense, counterclaim, claim, or objection in favor of the Borrowers or arising out of or with respect to any of the loans or other obligations of the Borrowers owed by the Borrowers under the Credit Agreement or any other Loan Document.
(c)    Loan Document. The parties hereto hereby acknowledge and agree that this Amendment is a Loan Document.
(d)    Effect of Amendment. Except as set forth expressly herein, all terms of the Credit Agreement and the other Loan Documents shall be and remain in full force and effect, and shall constitute the legal, valid, binding, and enforceable obligations of the Borrowers, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.
(e)    No Novation or Mutual Departure. The Borrowers expressly acknowledge and agree that (i) this Amendment does not constitute or establish, a novation with respect to the Credit Agreement or any of the other Loan Documents, or a mutual departure from the strict terms, provisions, and conditions thereof, other than with respect to the amendments set forth in Section 2 above, and (ii) nothing in this Amendment shall affect or limit the Administrative Agent’s or any Lender’s right to (x) demand payment of the Obligations under, or demand strict performance of the terms, provisions and conditions of, the Credit Agreement and the other Loan Documents (in each case, as amended), as applicable, (y) exercise any and all rights, powers, and remedies under the Credit Agreement or the other Loan Documents (in each case, as amended hereby) or at law or in equity, or (z) do any and all of the foregoing, immediately at any time during the occurrence of an Event of Default and in each case, in accordance with the terms and provisions of the Credit Agreement and the other Loan Documents (in each case, as amended hereby).
(f)    Release of Claims. In consideration of the agreement of the Administrative Agent and the Lender to enter into this Amendment, the Parent and the Loan Parties, on their behalf and on behalf of their respective successors and assigns, hereby fully, finally, and irrevocably release, acquit, and discharge the Administrative Agent, the Lenders and their Affiliates, and their respective officers, directors, representatives, agents, attorneys, advisors, employees, predecessors, successors, and assigns (collectively, the “Released Parties”), from any and all defenses, affirmative defenses, claims, counterclaims, offsets, cross claims, damages, demands, actions, judgments, suits, losses, out-of-pocket expenses, and causes of action of any kind or nature, whether in contract, tort, law, or equity, existing as of the date of this Amendment or based on facts or circumstances arising at any time up through and including the date of this Amendment, whether known or unknown, whenever and howsoever arising, in each case with respect to the Loan Documents, the Loans, and the Obligations. In addition, the Parent and the Loan Parties hereby agree not to commence, join



NAI-1509566825v8    4


in, prosecute, or participate (except to the extent required by law, including the rules and regulations of any exchange on which any Loan Party’s or Parent’s securities are then listed, quoted or otherwise admitted for trading) in any suit or other proceeding in a position adverse to that of any of the Released Parties arising directly or indirectly from any of the foregoing matters. If the Parent or the Loan Parties or any of their respective successors or assigns violate the foregoing covenant, the Parent and the Loan Parties, for themselves and their respective successors and assigns, jointly and severally agree to pay, in addition to (but without duplication of) such other damages as any Released Party may sustain as a result of such violation, all reasonable attorneys’ fees and costs incurred by any Released Party as a result of such violation.
(g)    Counterparts. This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same instrument. This Amendment may be executed by each party on separate copies, which copies, when combined so as to include the signatures of all parties, shall constitute a single counterpart of this Amendment.
(h)    Fax or Other Transmission. Delivery by one or more parties hereto of an executed counterpart of this Amendment via facsimile, telecopy, or other electronic method of transmission pursuant to which the signature of such party can be seen (including, without limitation, Adobe Corporation’s Portable Document Format) shall have the same force and effect as the delivery of an original executed counterpart of this Amendment. Any party delivering an executed counterpart of this Amendment by facsimile or other electronic method of transmission shall also deliver an original executed counterpart, but the failure to do so shall not affect the validity, enforceability, or binding effect of this Amendment.
(i)    Recitals Incorporated Herein. The preamble and the recitals to this Amendment are hereby incorporated herein by this reference.
(j)    Section References. Section titles and references used in this Amendment shall be without substantive meaning or content of any kind whatsoever and are not a part of the agreements among the parties hereto evidenced hereby.
(k)    Governing Law. This Amendment shall be governed by and construed in accordance with the internal laws (and not the law of conflicts) of the State of New York, but giving effect to federal laws applicable to national banks.
(l)    Severability. Any provision of this Amendment which is prohibited or unenforceable shall be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof in that jurisdiction or affecting the validity or enforceability of such provision in any other jurisdiction.
(m)    Reaffirmation of Loan Parties. Each Loan Party (i) consents to the execution and delivery of this Amendment, (ii) reaffirms all of its obligations and covenants under the Loan Documents (including, without limitation, the Collateral Documents and the Loan Guaranty) to which it is a party, and (iii) agrees that, except to the extent amended hereby, none of its respective



NAI-1509566825v8    5


obligations and covenants under the Loan Documents shall be reduced or limited by the execution and delivery of this Amendment.
(n)    Reaffirmation of Parent. Parent (i) consents to the execution and delivery of this Amendment, (ii) reaffirms all of its obligations and covenants under the Loan Documents (including, without limitation, the Collateral Documents) to which it is a party, and (iii) agrees that, except to the extent amended hereby, none of its obligations and covenants under the Loan Documents shall be reduced or limited by the execution and delivery of this Amendment.
(o)    Borrowing Base Calculation. For the avoidance of doubt, each party hereto acknowledges and agrees that the Borrowing Base calculated as of October 31, 2019 for the Borrowing Base Certificate delivered on or before November 20, 2019 and for each Borrowing Base Certificate thereafter shall be calculated after giving effect to this Amendment.
[SIGNATURES ON FOLLOWING PAGES.]




NAI-1509566825v8    6


IN WITNESS WHEREOF, the Borrowers, the other Loan Parties, the Administrative Agent and the Lenders have caused this Amendment to be duly executed by their respective duly authorized officers as of the day and year first above written.
BORROWERS:

BIO-REFERENCE LABORATORIES, INC.
GENEDX, INC.
FLORIDA CLINICAL LABORATORY, INC.
MERIDIAN CLINICAL LABORATORY CORP.


By:    /s/ Adam Logal        
Name:    Adam Logal
Title:    Vice President


OTHER LOAN PARTIES:

CAREEVOLVE.COM, INC.
BRLI-GENPATH DIAGNOSTICS, INC.
GENEDX MENA LLC


By:    /s/ Adam Logal        
Name:    Adam Logal
Title:    Vice President



[BRLI - Amendment No. 10 to Credit Agreement]
NAI-1509566825v8



ACKNOWLEDGED AND AGREED BY:

OPKO HEALTH, INC., as Parent


By:    /s/ Adam Logal        
Name:    Adam Logal
Title:    Sr. Vice President, CFO




[BRLI - Amendment No. 10 to Credit Agreement]
NAI-1509566825v8



JPMORGAN CHASE BANK, N.A.,
Individually as a Lender and as Administrative Agent, Issuing Bank and Swingline Lender


By:    /s/ Antje Focker        
Name:    Antje Focke
Title:    Executive Director


[BRLI - Amendment No. 10 to Credit Agreement]
NAI-1509566825v8



Exhibit A


COMMITMENT SCHEDULE
Lender
Revolving Commitment
JPMorgan Chase Bank, N.A.
$75,000,000
Total
$75,000,000


[BRLI - Amendment No. 10 to Credit Agreement]
NAI-1509566825v8


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
11/5/21
Filed on:3/2/204
For Period end:12/31/194
11/20/194
11/4/19
10/31/194
9/30/1910-Q,  SC 13D/A
8/6/19
2/26/19
2/28/18
12/22/178-K
11/8/1710-Q,  8-K
8/7/17
3/17/174,  8-K
9/26/164,  CT ORDER
2/29/1610-K,  4,  8-K
11/5/154,  8-K,  8-K/A
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/18/21  Opko Health, Inc.                 10-K       12/31/20  111:16M
Top
Filing Submission 0000944809-20-000007   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 5:57:23.1pm ET